NCT05229679 HPV-based Screening Among Women 23-29 Years of Age
| NCT ID | NCT05229679 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Human Papilloma Virus |
| Study Type | INTERVENTIONAL |
| Enrollment | 180,000 participants |
| Start Date | 2020-11-16 |
| Primary Completion | 2038-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180,000 participants in total. It began in 2020-11-16 with a primary completion date of 2038-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.
Eligibility Criteria
Inclusion Criteria: * Women ages 23-29 invited to screening. Exclusion Criteria: * Women who do not show up for screening or do not consent.
Contact & Investigator
Joakim Dillner, MD, PhD
PRINCIPAL INVESTIGATOR
Karolinska University Hospital/Karolinska Institutet
Frequently Asked Questions
Who can join the NCT05229679 clinical trial?
This trial is open to female participants only, aged 23 Years or older, up to 29 Years, studying Human Papilloma Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05229679 currently recruiting?
Yes, NCT05229679 is actively recruiting participants. Contact the research team at joakim.dillner@ki.se for enrollment information.
Where is the NCT05229679 trial being conducted?
This trial is being conducted at Lund, Sweden, Stockholm, Sweden.
Who is sponsoring the NCT05229679 clinical trial?
NCT05229679 is sponsored by Karolinska Institutet. The principal investigator is Joakim Dillner, MD, PhD at Karolinska University Hospital/Karolinska Institutet. The trial plans to enroll 180,000 participants.